ArrestageÂ® International, Inc. appoints Gary P. Croft as Chief Executive Officer
Arrestage® International, Inc., a licensor and marketer of proprietary aesthetic and dermal formulations, today announced that Gary P. Croft has been appointed the Company’s Chief Executive Officer.
Scottsdale, AZ (PRWEB) July 11, 2011
Arrestage® International, Inc., a licensor and marketer of proprietary aesthetic and dermal formulations, today announced that Gary P. Croft has been appointed the Company’s chief executive officer.
“We are delighted to announce Mr. Croft’s appointment as our Chief Executive Officer,” said Vice Chairman Kimberly Shapiro. “Gary brings us a great deal of commercial experience within aesthetics and dermatology and is an exceptionally strong executive having worked both domestically and overseas. His leadership will help shape Arrestage® International’s long-term strategic direction and will position the Company for the next level of growth.”
Mr. Croft brings over 26 years of experience in aesthetics and dermatology commercialization to Arrestage® International, as well as worldwide business development and leadership skills.
Before joining Arrestage® International, he was Vice President of Aesthetics at Merz Pharmaceuticals and more recently, President at The Aesthetics Group, an aesthetics and dermatology consulting company focused on business planning and marketing services. Mr. Croft led the Sales organization for Orthoneutrogena Aesthetics (Johnson and Johnson) in the U.S. and Canada and has held a variety of positions in Sales, Marketing, New Product Development and Business Development with Medicis, Glaxosmithkline and Aventis from 1985 through 2004.
“The chance to join Arrestage® International at this early stage of it’s development is an incredible opportunity,” said Mr. Croft. “Arrestage® is well positioned to enjoy significant growth and I look forward to leading the company as we grow our business both within the United States as well as throughout the rest of the world.”
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/7/prweb8629398.htm